BioMatrix Flex, LEADERS 4-Year Results

Biomatrix Flex™ - Cutting the MACE rate
out to 4 years

 


80% relative risk reduction in definite VLST
with BioMatrix Flex™

 


Reduction in definite VLST associated
with fewer cardiac events

 

 

Click here to see the presentation2


Read about the power of BA9™/PLA

“Our findings show that, compared with durable polymer SES, biodegradable polymer BES are non-inferior and can improve long-term clinical outcomes for up to 4 years. Our findings also show that they are associated with an 80% RR reduction compared with durable polymer SES in terms of very late definite ST occurring more than 1 year after stent implantation, with no difference in the risk of ST during the first year. The apparent benefit of biodegradable polymer BES was mainly attributable to a lower risk of primary endpoint events associated with very late definite ST.”2 © Copyright Elsevier 2011.

Click here to see more details about the Lancet publication3



* Based on Leaders results on MACE, definite VLST and cardiac events associated with definite stent thrombosis out to 4 years.
1. Stefanini GG et al., Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4-year follow-up of a randomized non-inferiority trial. The Lancet. 2011; 378(9807): 1940-8.
2. Ischinger T et al., Long-term clinical results from the all-comers LEADERS Trial: 4-year follow-up data, oral abstract presentation, TCT 2011.
3. The article was published in The Lancet, Vol 378: Stefanini GG et al., Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4-year follow-up of a randomised non-inferiority trial,_Pages 1940-1948. 
  11044-000-EN – Rev.01

 

CAUTION: The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.

Biosensors’ interventional cardiology products, including BioMatrix Flex™, BioMatrix NeoFlex™, BioMatrix™, Axxess™, BioFreedom™, Chroma™, BioStream™, BioPath™, Gazelle™, Juno™, S-Stent™, Powerline™, Quadrature Link™ and MultiPleat™, are not available for sale in the United States and certain other countries. All other trademarks are the property of their respective owners.

BioMatrix Flex, BioMatrix NeoFlex, BioMatrix, Axxess, BioFreedom, Chroma, BioStream, BioPath, Gazelle, Juno, S-Stent, Powerline, Quadrature Link and MultiPleat are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and certain other countries. All cited trademarks are the property of their respective owners.